lapatinib (GW572016)

DRUG3 trials

Sponsors

GlaxoSmithKline, Swedish Medical Center

Conditions

Breast CancerMetastatic Cervical CancerNeoplasms, Uterine CervixOvarian Epithelial Cancer Stage IIIStage IV Breast CancerStage IV Ovarian Cancer

Phase 1

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

CompletedNCT00316407

Swedish Medical CenterOvarian Epithelial Cancer Stage III, Stage IV Breast Cancer, Stage IV Ovarian Cancer

Start: 2005-08-31End: 2009-11-30Updated: 2011-02-18

Phase 2

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

CompletedNCT00430781

GlaxoSmithKlineMetastatic Cervical Cancer, Neoplasms, Uterine Cervix

Start: 2006-11-30End: 2011-07-31Updated: 2015-05-08

Phase 3

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

CompletedNCT00078572

GlaxoSmithKlineBreast Cancer

Start: 2004-03-31End: 2010-02-28Updated: 2010-12-13

Related Papers

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Journal of Clinical Oncology2020-07-17586 citations

Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.

Journal of Clinical Oncology2014-05-20

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

2011-10-1113 citations

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

2006-12-012308 citations